Skip to main content

Table 1 Clinical features between two groups

From: Surgical outcome of hepatocellular carcinoma patients with biliary tumor thrombi

Variables Group I (n = 27) Group II (n = 270) P value
Age (years)) 47.1 ± 10.5 48.0 ±11.3 0.272
Sex (Male/Female) 24/3 232/38 0.670
HBsAg-positive 26 (96.7%) 254 (94.1%) 0.636
Anti-HCV-positive 0 2 (1.2%) 0.654
Serum AFP (> 400 ng/ml) 16 (59.3%) 109 (40.3%) 0.058
Serum CA19-9 (> 37 U/ml) 13 (48.1%) 24 (8.8%) < 0.001
Serum total bilirubin (umol/L) 116.4 ± 135.4 14.5 ± 7.8 < 0.001
Serum ALT (IU/L) 132.2 ± 107.9 59.6 ± 53.0 < 0.001
Serum AST (IU/L) 95.58 ± 51.5 60.1 ± 53.8 < 0.001
Serum albumin (g/L) 40.4 ± 4.92 41.8 ± 5.6 0.326
Serum GGT (IU/L) 583.1 ± 372.4 122.9 ± 134.1 < 0.001
Serum ALP (IU/L) 305.4 ± 148.0 132.2 ± 83.1 < 0.001
  1. HBsAg: hepatitis B surface antigen. HCV: hepatitis C virus. AFP: alpha-fetoprotein.
  2. CA19-9: carbohydrate antigen19-9. BTT: biliary tumor thrombi.
  3. ALT: alanine aminotransferase. AST: aspartate aminotransferase. GGT: γ-glutamyl transpeptidase.
  4. ALP: alkaline phosphatase.